{"id":11592,"date":"2025-07-26T11:25:55","date_gmt":"2025-07-26T09:25:55","guid":{"rendered":"https:\/\/valintermed.com\/?p=11592"},"modified":"2025-07-26T11:25:55","modified_gmt":"2025-07-26T09:25:55","slug":"nasledstvennaya-koproporfiriya","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/","title":{"rendered":"Hereditary coproporphyria"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>Hereditary coproporphyria (HC) is a rare genetic disorder belonging to the group of porphyrias, characterized by a disorder of hemoglobin synthesis. This disorder is caused by a deficiency of certain enzymes in the metabolic pathway of porphyrin formation, in particular, porphobilinogen decarboxylase. Manifestations of the disease can be varied and include both acute abdominal pain and neuropsychiatric disorders. Episodes of exacerbation of the disease are often provoked by physical or emotional stress, use of certain medications, and dietary factors. <\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\" >Epidemiology<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\" >Genetic predisposition to this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Risk factors for the development of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Diagnosis of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\" >Treatment<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >List of medications used to treat this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Disease monitoring<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Age-related features of the disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/hereditary-co-ownership\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\" >Questions and Answers<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The history of studying porphyrias goes back more than a hundred years. The first mentions of symptoms similar to hereditary coproporphyria were made in the 19th century. In the 1920s, experiments with animals allowed scientists to identify the genetic nature of the disease and systematize its symptoms. Hereditary coproporphyria was first described in 1964, when it was established that the disease is associated with an enzyme deficiency, which led to the creation of a molecular theory of the disease. Interestingly, in various cultures, coproporphyria was often associated with &quot;mental&quot; diseases, which led to stigmatization of patients and misunderstanding of this condition.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\"><\/span>Epidemiology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hereditary coproporphyria occurs with a frequency of about 1 in 200,000 people in the general population. However, this figure can vary significantly depending on ethnicity and geographic location. For example, the incidence is higher in Norway and Sweden, which may be due to the genetic makeup of the populations in these countries. Women are more susceptible to the disease than men, especially during reproductive age, due to the influence of hormones on porphyrin metabolism.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\"><\/span>Genetic predisposition to this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hereditary coproporphyria is an autosomal dominant disorder, meaning that only one mutated gene is needed to cause the disease. The gene responsible for inappropriate levels of porphyrin particles is called CPOX (coproporphyrin hydroxylase), which is located on chromosome 3. More than 30 different mutations of this gene have been identified, indicating the complexity and diversity of the genetic basis of this disease. Research shows that some mutations can cause a more severe course of the disease, while others remain virtually asymptomatic.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Risk factors for the development of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Risk factors for hereditary coproporphyria can be divided into several groups:<\/p>\n<ul>\n<li>Physical factors:<\/li>\n<ul>\n<li>Exercises that cause physical stress.<\/li>\n<li>Environmental influences: eg high temperatures.<\/li>\n<\/ul>\n<li>Chemical factors:<\/li>\n<ul>\n<li>Use of certain medications, such as barbiturates and some birth control pills.<\/li>\n<li>Drinking alcohol, which can provoke an exacerbation of the disease.<\/li>\n<\/ul>\n<li>Other factors:<\/li>\n<ul>\n<li>Emotional stress.<\/li>\n<li>Infectious diseases that can provoke episodic exacerbation.<\/li>\n<\/ul>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Diagnosis of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnosis of hereditary coproporphyria requires a comprehensive approach. Symptoms of the disease include:<\/p>\n<ul>\n<li>Acute abdominal pain.<\/li>\n<li>Neuropsychiatric symptoms such as anxiety and depression.<\/li>\n<li>Psychoses and neuroses in the acute phase of the disease.<\/li>\n<\/ul>\n<p>Laboratory tests play an important role: <\/p>\n<ul>\n<li>Urine analysis for the presence of porphyrins, which in NC show high levels of coproporphyrin.<\/li>\n<li>Comparative analysis of the level of porphyrins and their precursors in the blood.<\/li>\n<li>Genetic testing for mutations in the CPOX gene.<\/li>\n<\/ul>\n<p>Radiological studies such as MRI and CT scans may be used to rule out other causes of abdominal pain and neurological disorders. The differential diagnosis includes ruling out other forms of porphyria as well as gastrointestinal disorders.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\"><\/span>Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Treatment of hereditary coproporphyria consists of several components:<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<ul>\n<li>General treatment:<\/li>\n<ul>\n<li>Following a diet that excludes provoking factors (alcohol, medications).<\/li>\n<\/ul>\n<li>Pharmacological treatment:<\/li>\n<ul>\n<li>Glucose infusions for assessing the condition of patients in the acute period.<\/li>\n<li>The use of heme antacids, which help reduce the level of coproporphyrin in the body.<\/li>\n<li>Medicines that reduce stress and anxiety levels.<\/li>\n<\/ul>\n<li>Surgical treatment:<\/li>\n<ul>\n<li>Surgery may be required in case of complications associated with gastrointestinal diseases.<\/li>\n<\/ul>\n<li>Other types of treatment:<\/li>\n<ul>\n<li>Maintaining water-electrolyte balance and avoiding massive physical stress.<\/li>\n<\/ul>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>List of medications used to treat this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the drugs recommended for the treatment of hereditary coproporphyria are:<\/p>\n<ul>\n<li>Gem antacids.<\/li>\n<li>Glucose for infusions.<\/li>\n<li>Benzodiazepines to reduce anxiety levels.<\/li>\n<li>Painkillers for pain relief.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Disease monitoring<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Monitoring the condition of a patient with hereditary coproporphyria plays a key role in disease management. Monitoring steps include:<\/p>\n<ul>\n<li>Regular analysis of porphyrin levels in urine and blood.<\/li>\n<li>Examinations to monitor for complications (eg, CT or MRI).<\/li>\n<li>Feedback to the doctor to assess the state of the nervous system.<\/li>\n<\/ul>\n<p>The prognosis with proper monitoring and attention to signs of the disease is usually good, but serious complications such as liver failure and psychosis may occur, which require immediate intervention.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Age-related features of the disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Hereditary coproporphyria can manifest itself at different ages. <\/p>\n<ul>\n<li>In children:<\/li>\n<ul>\n<li>Severe symptoms may develop at an early age, often due to infections.<\/li>\n<\/ul>\n<li>In adolescents and young adults:<\/li>\n<ul>\n<li>The risk of exacerbations increases significantly during puberty.<\/li>\n<\/ul>\n<li>In the elderly:<\/li>\n<ul>\n<li>Symptoms may be less severe, but the risk of complications increases at this age.<\/li>\n<\/ul>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\"><\/span>Questions and Answers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>What are the main symptoms of hereditary coproporphyria?<\/strong> The main symptoms include acute abdominal pain, mental disorders and changes in urine (high levels of porphyrins).<\/li>\n<li><strong>How is the disease diagnosed?<\/strong> Diagnosis includes urine testing, blood tests, and genetic testing for mutations in the CPOX gene.<\/li>\n<li><strong>What are the risk factors for flare-ups?<\/strong> Major risk factors include stress, certain medications and alcohol.<\/li>\n<li><strong>What is the prognosis if the disease is present?<\/strong> The prognosis with proper monitoring and treatment is usually positive, but serious complications are possible.<\/li>\n<li><strong>What medications are recommended for treatment?<\/strong> Treatment includes heme antacids, glucose injections, and anti-anxiety medications.<\/li>\n<\/ul>\n<p>Dr. Oleg Korzhikov notes that patients with hereditary coproporphyria should actively participate in managing their condition and protect themselves from potential triggers, such as stress and certain medications. \u201cIt is important to know your limitations and avoid unnecessary stress,\u201d he adds. The doctor also advises staying in touch with your doctor and not ignoring any sexual communication about your symptoms, as this can be key to preventing flare-ups.<\/p>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Hereditary coproporphyria (HC) is a rare genetic disorder belonging to the group of porphyrias, characterized by a disorder of hemoglobin synthesis. This disorder is caused by a deficiency<\/p>","protected":false},"author":1,"featured_media":19545,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-11592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=11592"}],"version-history":[{"count":1,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11592\/revisions"}],"predecessor-version":[{"id":15623,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/11592\/revisions\/15623"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media\/19545"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=11592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=11592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=11592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}